AT282

AT282 is an undisclosed, hospital-focused, ready-to-use (RTU) liquid concentrate formulation of an existing marketed injectable product that is currently only available as a lyophilised powder. Developed using Arecor Therapeutics’ Arestat formulation technology, AT282 is designed to provide a stable, ready-to-use presentation that simplifies preparation, reduces the risk of dosing and reconstitution errors, and improves workflow and safety in the hospital setting. The specific active pharmaceutical ingredient, target, and therapeutic indication have not been publicly disclosed, but the product is positioned within Arecor’s specialty hospital portfolio as a reformulation of an established injectable therapy for intravenous use.[1][5][9][11][13][14]